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Because of the qualitative nature of the studies on myocardial 
glucose utilization in our report, it is not possible to exclude the 
third possibility of globally abnormal glucose metabolism as sug- 
gested by Joyce. However, there is no evidence in published studies 
or in this investigation to support such a notion. Rather, most of the 
available evidence in classic hypertrophic cardiomyopathy points to 
an abnormality affecting primarily the disproportionately thickened 
interventricular septum and not the lateral wag (13-16). Our studies 
with PET in patients with hypertrophic cardiomyopathy indicated 
that C-l 1 palmitate kinetics in the septum were similar to those in 
the lateral wall and to those in normal myocardium. suggesting that 
fatty acid metabolism was normally preserved. In contrast, the 
relative reduction of N-13 ammonia uptake in the septum compared 
with that in the lateral wall indicated a relative decrease in blood 
flow. Importantly, the even greater reduction (rather than an in- 
crease) in glucose utilization argues against the presence of ischemia 
in the interventricular septum. Our study offered one potential 
mechanism for this relative decrease in tracer uptake in the septum 
as compared with the lateral wall. However, this mechanism re- 
mains speculative at present. Our initial observations of this meta- 
bolic abnormality in patients with hypertrophic cardiomyopathy will 
require further investigations to elucidate the underlying mechanism 
or mchanisms. As new positron tracers are developed, it will be 
possible in the future to examine with positron emission tomography 
other aspects of substrate metabolism and of neural and hormonal 
control. This should provide further understanding of the patho- 
physiology underlying our observation. 
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Correction 
In Gottlieb et al. (J Am Coil Cardiol 1989;13:1534-9), the 
greater than and less than symbols in Tables 1 and 2 should 
be reversed. In the two columns headed ANP, “>” should 
appear as “<” and “<” should appear as “>“. 
